PFO
CCXI

Pathstone Family Office’s ChemoCentryx, Inc. CCXI Stock Holding History

Pathstone Family Office’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-769
Closed -$3K – 344
2013
Q3 		$3K Buy
+769
New +$8.31K 0.01% 266

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pathstone Family Office's CCXI Position: Q4 2013 in Review

Pathstone Family Office sold out of ChemoCentryx, Inc. (CCXI) in Q4 2013, closing a stake of 769 shares — an estimated $3K sold.

Pathstone Family Office first reported a position in CCXI in Q3 2013 and held it in 1 quarter. The position peaked at $3K in Q3 2013. 60 funds tracked by Wall St. Rank hold CCXI as of Q4 2013.

  • Pathstone Family Office reported no remaining ChemoCentryx, Inc. position as of Q4 2013 after selling out during the quarter.
  • Pathstone Family Office sold 769 ChemoCentryx, Inc. shares in Q4 2013, an estimated $3K.
  • Pathstone Family Office first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 1 quarter.
  • Pathstone Family Office's ChemoCentryx, Inc. position peaked at $3K in Q3 2013.
  • 60 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2013.

Based on Pathstone Family Office's 13F filing for Q4 2013, filed 4 Feb 2014.